Literature DB >> 20145161

Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.

Jessica H Maxwell1, Bhavna Kumar, Felix Y Feng, Francis P Worden, Julia S Lee, Avraham Eisbruch, Gregory T Wolf, Mark E Prince, Jeffrey S Moyer, Theodoros N Teknos, Douglas B Chepeha, Jonathan B McHugh, Susan G Urba, Jay Stoerker, Heather M Walline, David M Kurnit, Kitrina G Cordell, Samantha J Davis, Preston D Ward, Carol R Bradford, Thomas E Carey.   

Abstract

PURPOSE: The goal of this study was to examine the effect of tobacco use on disease recurrence (local/regional recurrence, distant metastasis, or second primary) among patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) following a complete response to chemoradiation therapy. EXPERIMENTAL
DESIGN: Between 1999 and 2007, 124 patients with advanced SCCOP (86% with stage IV) and adequate tumor tissue for HPV analysis who were enrolled in one of two consecutive University of Michigan treatment protocols were prospectively included in this study. Patients were categorized as never-, former, or current tobacco users. The primary end points were risk of disease recurrence and time to recurrence; secondary end points were disease-specific survival and overall survival.
RESULTS: One hundred and two patients (82.3%) had HPV-positive tumors. Over two thirds (68%) of patients with HPV-positive tumors were tobacco users. Among HPV-positive patients, current tobacco users were at significantly higher risk of disease recurrence than never-tobacco users (hazard ratio, 5.2; confidence interval, 1.1-24.4; P = 0.038). Thirty-five percent of HPV-positive ever tobacco users recurred compared with only 6% of HPV-positive never users and 50% of HPV-negative patients. All HPV-negative patients were tobacco users and had significantly shorter times to recurrence (P = 0.002), and had reduced disease-specific survival (P = 0.004) and overall survival (P < 0.001) compared with HPV-positive patients. Compared with HPV-positive never-tobacco users, those with a tobacco history showed a trend for reduced disease-specific survival (P = 0.064) but not overall survival (P = 0.221).
CONCLUSIONS: Current tobacco users with advanced, HPV-positive SCCOP are at higher risk of disease recurrence compared with never-tobacco users.

Entities:  

Mesh:

Year:  2010        PMID: 20145161      PMCID: PMC2822887          DOI: 10.1158/1078-0432.CCR-09-2350

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma.

Authors:  K Lindel; K T Beer; J Laissue; R H Greiner; D M Aebersold
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

2.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

3.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

4.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

5.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

Authors:  Bhavna Kumar; Kitrina G Cordell; Julia S Lee; Francis P Worden; Mark E Prince; Huong H Tran; Gregory T Wolf; Susan G Urba; Douglas B Chepeha; Theodoros N Teknos; Avraham Eisbruch; Christina I Tsien; Jeremy M G Taylor; Nisha J D'Silva; Kun Yang; David M Kurnit; Joshua A Bauer; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

6.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

Authors:  Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

7.  Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.

Authors:  Harriët C Hafkamp; J J Manni; A Haesevoets; A C Voogd; M Schepers; F J Bot; A H N Hopman; F C S Ramaekers; Ernst-Jan M Speel
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

8.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

Authors:  Maura L Gillison; Gypsyamber D'Souza; William Westra; Elizabeth Sugar; Weihong Xiao; Shahnaz Begum; Raphael Viscidi
Journal:  J Natl Cancer Inst       Date:  2008-03-11       Impact factor: 13.506

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma.

Authors:  Elizabeth A Sisk; Scott G Soltys; Shaobo Zhu; Susan G Fisher; Thomas E Carey; Carol R Bradford
Journal:  Head Neck       Date:  2002-09       Impact factor: 3.147

View more
  97 in total

1.  UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line.

Authors:  Alice L Tang; Samantha J Hauff; John H Owen; Martin P Graham; Michael J Czerwinski; Jung Je Park; Heather Walline; Silvana Papagerakis; Jay Stoerker; Jonathan B McHugh; Douglas B Chepeha; Carol R Bradford; Thomas E Carey; Mark E Prince
Journal:  Head Neck       Date:  2011-12-13       Impact factor: 3.147

2.  Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.

Authors:  Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek
Journal:  Head Neck       Date:  2016-07-19       Impact factor: 3.147

3.  Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.

Authors:  William Strober; Sachie Shishido; Burton Wood; James S Lewis; Krystle Kuhs; Robert L Ferris; Daniel L Faden
Journal:  Oral Oncol       Date:  2019-11-22       Impact factor: 5.337

4.  Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study.

Authors:  Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-29       Impact factor: 2.503

Review 5.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

6.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Authors:  Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

Review 7.  HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection.

Authors:  Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

8.  Impact of Smoking on the Survival of Patients With High-risk HPV-positive HNSCC: A Meta-analysis.

Authors:  Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Matthew E Spector; Mohannad Ibrahim; Carol R Bradford; Gregory T Wolf; Matthew H Stenmark; Francis P Worden; Jonathan B McHugh; Mark E Prince; Thomas Carey; Douglas B Chepeha; Avraham Eisbruch
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

Review 10.  Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.

Authors:  Elaine O Bigelow; Tanguy Y Seiwert; Carole Fakhry
Journal:  Oral Oncol       Date:  2020-04-02       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.